Kavalactone product
US7001620B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Apr 8, 2003 |
| Grant date | Feb 21, 2006 |
| Priority date | — |
| Expiry date | Apr 8, 2023 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D309/40
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is a method for enhancing the efficacy of an active ingredient in a human comprising: administering to said human a product comprising: a kavalactone component and an active ingredient, wherein said active ingredient is selected from the group consisting of a therapeutic, a pharmaceutical, a nutraceutical and a botanical, and wherein said kavalactone component comprises a methysticin component, a dihydromethysticin component, a desmethoxyyangonin component, a yangonin component, a dihydrokavain component, and a kavain component, and wherein said kavalactone component is between about 0.1% to about 75%, by mass, of said product.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.